Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cipaglucosidase alfa/miglustat in pediatric infantile-onset Pompe disease
NCT04808505Phase 3Recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Jul 2023
- Primary completion
- Jul 2027
- Modality
- Replacement Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of cipaglucosidase alfa in Pompe disease, sponsored by Amicus Therapeutics. Started Jul 2023; status: recruiting.
02
Drugs
cipaglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT04808505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808505.